Antithrombotic drugs

Bibliography

• KESSELS H, KESTER AD, HEMKER HC: Intrinsic and method-induced variation of the bleeding time and related parameters. Thromb. Haemost. (1994) 71:798–799.
   PubMed Web of Science ®Google Scholar
• AGNELLI G: Thrombin plays a pivotal role in vascular re-occlusion after PTCA and coronary thrombolysis. Cardiovasc. Res. (1996) 31:232–234.
   PubMed Web of Science ®Google Scholar
• BADIMON L, MEYER BJ, BADIMON JJ: Thrombin in arterial thrombosis. Haemostasis (1994) 24:69–80.
   PubMedGoogle Scholar
• CHESEBRO JH, ZOLDHELYI P, BADIMON L, FUSTER V: Role of thrombin in arterial thrombosis: implications for therapy. Thromb. Haemost. (1991) 66:1–5.
   PubMed Web of Science ®Google Scholar
• CHESEBRO JH, RAUCH U, FUSTER V, BADIMON JJ: Pathogenesis of thrombosis in coronary artery disease. Haemostasis (1997) 27:12–18.
   PubMedGoogle Scholar
• FITZGERALD GA: The human pharmacology of thrombin inhibition. [Coron. Artery Dis. (1997) 8(1):A41. Coron. Artery Dis. (1996) 7:911–918.
   PubMed Web of Science ®Google Scholar
• •Excellent overview.
   Google Scholar
• SCHECTER AD, GIESEN PL, TABY O, et al.: Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J. Clin. Invest. (1997) 100:2276–2285.
   PubMed Web of Science ®Google Scholar
• TOSCHI V, GALLO R, LETTINO M, et al.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 95:594–599.
   PubMed Web of Science ®Google Scholar
• WILCOX JN, SMITH KM, SCHWARTZ SM, GORDON D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA (1989) 86:2839.
   PubMed Web of Science ®Google Scholar
• MARMUR JD, THIRUVIKRAMAN SV, FYFE BS, et al.: Identification of active tissue factor in human coronary atheroma. Circulation (1996) 94:1226.
   PubMed Web of Science ®Google Scholar
• HEEMSKERK JVV, VUIST WM, FEIJGE MA, REUTELINGSPERGER CP, LINDHOUT T: Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood (1997) 90:2615.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Evidence-based health policy - lessons from the Global Burden of Disease Study. Science (1996) 274:740.
   PubMed Web of Science ®Google Scholar
• FUSTER VVM: Thrombosis in Cardiovascular Disorders. WB Saunders, Philadelphia, USA (1992).
   Google Scholar
• BARROWCLIFFE T: Low Molecular Weight Heparins. Contains essential information on low molecular weight heparins.
   Google Scholar
• HEMKER HC, BEGUIN S: The activity of heparin in the presence and absence of Ca2+ ions; why the anti-Xa activity of LMW heparins is about two times overestimated. Thromb. Haemost. (1993) 70:717.
   PubMed Web of Science ®Google Scholar
• BENDETOWICZ AV, BEGUIN S, CAPLAIN H, HEMKER HC: Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin-a three way cross over study in human volunteers. Thromb. Haemost. (1994) 71:305.
   PubMed Web of Science ®Google Scholar
• BENDETOWICZ AV, KAI H, KNEBEL R, et al.: The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma - a study in human volunteers. Thromb. Haemost. (1994) 72:705.
   PubMed Web of Science ®Google Scholar
• HEMKER HC, BEGUIN S, KAKKAR VV: Can the haemorrhagic component of heparin be identified Or an attempt at clean thinking on a dirty drug [editorial]. Haemostasis (1996) 26:117.
   PubMedGoogle Scholar
• TOLLEFSEN DM, BLANK MK: Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J. Clin. Invest. (1981) 68:589.
   PubMed Web of Science ®Google Scholar
• DOL F, PETITOU M, CHOAY J, SIE P, HOUIN G, BONEU B: Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives. Folio Haematol. Int. Mag. Klin. Morphol. Blutforsch (1989) 116:851.
   PubMedGoogle Scholar
• DOL F, CARANOBE C, DUPOUY D, et al.: Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties. Thromb. Res. (1988) 52:153.
   PubMed Web of Science ®Google Scholar
• BENDAYAN P, BOCCALON H, DUPOUY D, BONEU B: Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb. Haemost. (1994) 71:576.
   PubMed Web of Science ®Google Scholar
• LOSONCZY H, DAVID M, NAGY I: Effect of pentosan polysulfate on activated partial thromboplastin time, thrombin time, euglobulin clot lysis, and on tissue-type plasminogen activator and plasminogen activator inhibitor activities in patients with thromboembolic disease. Semin. Thromb. Hemost. (1991) 17:394.
   PubMed Web of Science ®Google Scholar
• MAURAY S, STERNBERG C, THEVENIAUX J, et al.: Venous antithrombotic and anticoagulant activities of a fucoidan fraction. Thromb. Haemost. (1995) 74:1280.
   PubMed Web of Science ®Google Scholar
• SCHENK JF, GLUSA E, RADZIWON P, BUTTI A, MARKWARDT F, BREDDIN HK: A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time. Haemostasis (1996) 26:187.
   PubMedGoogle Scholar
• SCHENK JF, GLUSA E, RADZIWON P, BUTTI A, MARKWARDT F, BREDDIN HK: A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Haemostasis (1996) 26:140.
   PubMedGoogle Scholar
• MARKWARDT F: The development of hirudin as an antithrombotic drug. Thromb. Res. (1994) 74:1.
   PubMed Web of Science ®Google Scholar
• WALSMANN P: Isolation and characterization of hirudin from Hirudo medicinalis. Semin. Thromb. Hemost. (1991) 17:83.
   PubMed Web of Science ®Google Scholar
• FITZGERALD D: Specific thrombin inhibitors in vivo. Ann. NY Acad. Sci. (1994) 714: 41.
   PubMed Web of Science ®Google Scholar
• •Excellent overview.
   Google Scholar
• GAST A, TSCHOPP TB, BAUMGARTNER HR: Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler. Thromb. (1994) 14:1466.
   PubMedGoogle Scholar
• HERAS M, CHESEBRO JH, PENNY WJ, BAILEY KR, BADIMON L, FUSTER V: Effects of thrombin inhibition on the development of acute platelet- thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation (1989) 79:657.
   PubMed Web of Science ®Google Scholar
• JANG IK, GOLD HK, ZISKIND AA, LEINBACH RC, FALLON JT, COLLEN D: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation (1990) 81:219.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, TOPOL EJ: Direct thrombin inhibitors in cardiovascular medicine. Circulation (1994) 90:1522.
   PubMed Web of Science ®Google Scholar
• LAM KS, SALMON SE, HERSH EM, HRUBY VJ, KAZMIERSKI WM, KNAPP RJ: A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 354:82.
   PubMed Web of Science ®Google Scholar
• OSTREM JA, AL-OBEIDI F, SAFAR P, et al.: Discovery of a novel, potent, and specific family of Factor Xa inhibitors via combinatorial chemistry. Biochemistry (1998) 37:1053.
   PubMed Web of Science ®Google Scholar
• AROCAS V, ZINGALI RB, GUILLIN MC, BON C, JANDROT-PERRUS M: Bothrojaracin: a potent two-site-directed thrombin inhibitor. Biochemistry (1996) 35:9083.
   PubMed Web of Science ®Google Scholar
• CAPPELLO M, BERGUM PW, VLASUK GP, FURMIDGE BA, PRITCHARD DI, AKSOY S: Isolation and characterization of the tsetse thrombin inhibitor: a potent antithrombotic peptide from the saliva of Glossina morsitans morsitans. Am. J. Trop. Med. Hyg. (1996) 54:475.
   PubMed Web of Science ®Google Scholar
• FRIEDRICH T, KROGER B, BIALOJAN S, et al.: A Kazal-type inhibitor with thrombin specificity from Rhodnius prolixus. J. Biol. Chem. (1993) 268: 16216.
   PubMed Web of Science ®Google Scholar
• HOFFMANN A, WALSMANN P, RIESENER G, PAINTZ M, MARKWARDT F: Isolation and characterization of a thrombin inhibitor from the tick ixodes ricinus. Pharmazie (1991) 46:209.
   PubMed Web of Science ®Google Scholar
• KODANI S, ISHIDA K, MURAKAMI M: Aeruginosin 103-A, a thrombin inhibitor from the cyanobacterium Microcystis viridis. J. Nat. Prod. (1998) 61: 1046.
   PubMed Web of Science ®Google Scholar
• REBELLO SS, MILLER By, BASLER GC, LUCCHESI BR: CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J. Cardiovasc. Pharmacol. (1997) 29:240.
   PubMed Web of Science ®Google Scholar
• A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients. A double- blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur. Heart J. (1997) 18:1416.
   PubMed Web of Science ®Google Scholar
• URIUDA Y, WANG QD, GRIP L, RYDEN L, SJOQUIST PO, MATTSSON C: Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. Cardiovasc. Res. (1996) 32:320.
   PubMed Web of Science ®Google Scholar
• URIUDA Y, WANG QD, HATORI N, et al.: Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. J. Pharmacol. Toxicol. Methods (1998) 39:81.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON D, ELG M, LENFORS S, BORJESSON I, TEGER-NILSSON AC: Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul. Fibrinolysis (1996) 7:69.
   PubMed Web of Science ®Google Scholar
• GUSTAFSSON D, ANTONSSON T, BYLUND R, et al.: Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. (1998) 79:110.
   PubMed Web of Science ®Google Scholar
• MEHTA JL, CHEN L, NICHOLS WW, MATTSSON C, GUSTAFSSON D, SALDEEN TG: Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J. Cardiovasc. Pharmacol. (1998) 31:345.
   PubMed Web of Science ®Google Scholar
• ROUX S, TSCHOPP T, BAUMGARTNER HR: Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J. Pharmacol. Exp. Ther. (1996) 277:71.
   PubMed Web of Science ®Google Scholar
• •References 13–15: a few examples among many others of thrombin inhibitors.
   Google Scholar
• BRADY SF, STAUFFER KJ, LUMMA WC, et al.: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)proly1 trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure- based design and rapid multiple analogue synthesis on solid support. J. Med. Chem. (1998) 41:401.
   PubMed Web of Science ®Google Scholar
• CADROY Y, CARANOBE C, BERNAT A, MAFFRAND JP, SIE P, BONEU B: Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit. Thromb. Haemost. (1987) 58:764.
   PubMed Web of Science ®Google Scholar
• CIRILLO R, LIPPI A, SUBISSI A, AGNELLI G, CRISCUOLI M: Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor. Thromb. Haemost. (1996) 76:384.
   PubMed Web of Science ®Google Scholar
• DESCHENES I, FINKLE CD, WINOCOUR PD: Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model. Thromb. Haemost. (1998) 80:186.
   PubMed Web of Science ®Google Scholar
• FINKLE CD, ST. PIERRE A, LEBLOND L, DESCHENES I, DIMAIO J, WINOCOUR PD: BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis-comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb. Haemost. (1998) 79:431.
   PubMed Web of Science ®Google Scholar
• GRIFFIN LC, TOOLE JJ, LEUNG LL: The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene (1993) 137:25.
   PubMed Web of Science ®Google Scholar
• HARA H, TAMAO Y, KIKUMOTO R, OKAMOTO S: Effect of a synthetic thrombin inhibitor MCI-9038 on experimental models of disseminated intravascular coagulation in rabbits. Thromb. Haemost. (1987) 57:165.
   PubMed Web of Science ®Google Scholar
• HIJIKATE A, OKAMOTO S, IKEZAWA K, KIKIMOTO R, TONOMURA S, TAMAO Y: Proceedings: animal experiments of a new synthetic thrombin-inhibitor, dansyl-arginine-methyl-piperidine amide. Thromb. Diath. Haemorrh. (1975) 34:347.
   PubMedGoogle Scholar
• HUSSAIN MA, KNABB R, AUNGST BJ, KETTNER C: Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats. Peptides (1991) 12:1153.
   PubMed Web of Science ®Google Scholar
• IKOMA H, OHTSU K, TAMAO Y, et al.: Effect of a potent thrombin inhibitor, No. 407, on novel experimental thrombosis generated by acetic acid. Kobe J. Med. Sci. (1980) 26:33.
   PubMedGoogle Scholar
• KAISER B, HAUPTMANN J, WEISS A, MARKWARDT F: Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta (1985) 44:1201.
   PubMedGoogle Scholar
• OKAYAMA T, ARAKI S, MIYAMAE T, MORITA Y, MORIKAWA T, HAGIVVARA M: Anticoagulant activity of the novel thrombin inhibitor 1 -buty1-3 -(6,7-dimethoxy-2-naphthylsulfonyl) amino-3-(3-guanidinopropy1)-2- pyrrolidinone hydrochloride. Arzneimittelforschung (1997) 47:1023.
   PubMed Web of Science ®Google Scholar
• NOESKE-JUNGBLUT C, HAENDLER B, DONNER P, ALAGON A, POSSANI L, SCHLEUNING WD: Triabin, a highly potent exosite inhibitor of thrombin. J. Biol. Chem. (1995) 270:28629.
   PubMed Web of Science ®Google Scholar
• RUPIN A, MENNECIER P, LILA C, DE NANTEUIL G, VERBEUREN TJ: Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Thromb. Haemost. (1997) 78:1221.
   PubMed Web of Science ®Google Scholar
• SHUMAN RT, GESELLCHEN PD: Development of an orally active tripeptide arginal thrombin inhibitor. Pharm. Biotechnol. (1998) 11: 57.
   PubMedGoogle Scholar
• TAPPARELLI C, METTERNICH R, EHRHARDT C, et al.: In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J. Biol. Chem. (1993) 268:4734.
   PubMed Web of Science ®Google Scholar
• TREMOLI E, COLLI S, PAOLETTI R: GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: 'in vitro' and 'in vivo' studies. Adv. Exp. Med. Biol. (1984) 164:187.
   PubMedGoogle Scholar
• BAGDY D, BARABAS E, FITTLER Z, et al.: Experimental oral anticoagulation by a directly acting thrombin inhibitor (RGH-2958). Folio Haematol. Int. Mag. Klin. Morphol. Blutforsch (1988) 115:136.
   PubMedGoogle Scholar
• ANDERSEN K, DELLBORG M: Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am. J. Cardiol. (1998) 81:939.
   PubMed Web of Science ®Google Scholar
• LUNVEN C, GAUFFENY C, LECOFFRE C, O'BRIEN DP, ROOME NO, BERRY CN: Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb. Haemost. (1996) 75:154.
   PubMed Web of Science ®Google Scholar
• APITZ-CASTRO R, BEGUIN S, TABLANTE A, BARTOLI F, HOLT JC, HEMKER HC: Purification and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus). Thromb. Haemost. (1995) 73: 94.
   PubMed Web of Science ®Google Scholar
• DUNWIDDIE C, THORNBERRY NA, BULL HG, et al.: Antistasin, a leech-derived inhibitor of Factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J. Biol. Chem. (1989) 264:16694.
   PubMed Web of Science ®Google Scholar
• •References 20 & 21; two among the many natural Factor Xa inhibitors.
   Google Scholar
• DUNWIDDIE CT, SMITH DE, NUTT EM, VLASUK GP: Anticoagulant effects of the selective Factor XA inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition. Thromb. Res. (1991) 64:787.
   PubMed Web of Science ®Google Scholar
• DUNWIDDIE CT, NEEPER MP, NUTT EM, et al.: Site-directed analysis of the functional domains in the Factor Xa inhibitor tick anticoagulant peptide: identification of two distinct regions that constitute the enzyme recognition sites. Biochemistry (1992) 31:12126.
   PubMed Web of Science ®Google Scholar
• HAUPTMANN J, KAISER B: Anticoagulant and antithrombotic action of the Factor Xa inhibitor antistasin (ATS). Thromb. Res. (1993) 71:169.
   PubMedGoogle Scholar
• HERAULT JP, BERNAT A, PFLIEGER AM, LORMEAU JC, HERBERT JM: Comparative effects of two direct and indirect Factor Xa inhibitors on free and clot-bound prothrombinase. J. Pharmacol. Exp. Ther. (1997) 283:16.
   PubMed Web of Science ®Google Scholar
• JORDAN SP, WAXMAN L, SMITH DE, VLASUK GP: Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation Factor Xa. Biochemistry (1990) 29:11095.
   PubMed Web of Science ®Google Scholar
• JORDAN SP, MAO SS, LEWIS SD, SHAFER JA: Reaction pathway for inhibition of blood coagulation Factor Xa by tick anticoagulant peptide. Biochemistry (1992) 31:5374.
   PubMed Web of Science ®Google Scholar
• KATAKURA S, NAGAHARA T, HARA T, IVVAMOTO M: A novel Factor Xa inhibitor: structure-activity relationships and selectivity between Factor Xa and thrombin. Biochem. Biophys. Res. Commun. (1993) 197:965.
   PubMed Web of Science ®Google Scholar
• MAO SS, HUANG J, WELEBOB C, NEEPER MP, GARSKY VM, SHAFER JA: Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human Factor Xa. Biochemistry (1995) 34:5098.
   PubMed Web of Science ®Google Scholar
• MORISHIMA Y, TANABE K, TERADA Y, HARA T, KUNITADA S: Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective Factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb. Haemost. (1997) 78:1366.
   PubMed Web of Science ®Google Scholar
• NUTT E, GASIC T, RODKEY J, et al.: The amino acid sequence of antistasin. A potent inhibitor of Factor Xa reveals a repeated internal structure. J. Biol. Chem. (1988) 263:10162.
   PubMed Web of Science ®Google Scholar
• NUTT EM, JAIN D, LENNY AB, SCHAFFER L, SIEGL PK, DUNWIDDIE CT: Purification and characterization of recombinant antistasin: a leech- derived inhibitor of coagulation Factor Xa. Arch. Biochem. Biophys. (1991) 285:37.
   PubMed Web of Science ®Google Scholar
• PRASA D, SVENDSEN L, STURZEBECHER J: Inhibition of thrombin generation in plasma by inhibitors of Factor Xa. Thromb. Haemost. (1997) 78:1215.
   PubMed Web of Science ®Google Scholar
• SCHREUDER H, ARKEMA A, DE BOER B, et al.: Crystallization and preliminary crystallographic analysis of antistasin, a leech-derived inhibitor of blood coagulation Factor Xa. J. Mol. Biol. (1993) 231:1137.
   PubMed Web of Science ®Google Scholar
• VLASUK GP: Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation Factor Xa. Thromb. Haemost. (1993) 70:212.
   PubMed Web of Science ®Google Scholar
• WAXMAN L, SMITH DE, ARCURI KE, VLASUK GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation Factor Xa. Science (1990) 248:593.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI M, ASAKURA H, AOSHIMA K, et al.: Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of Factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb. Haemost. (1994) 72:392.
   PubMedGoogle Scholar
• JOHNSON K, HUNG D: Novel anticoagulants based on inhibition of the Factor VIIa/tissue factor pathway. Coron. Artery Dis. (1998) 9:83.
   PubMed Web of Science ®Google Scholar
• HUANG M, SYED R, STURA EA, et al.: The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF.G9 complex. J. Mol. Biol. (1998) 275:873.
   PubMed Web of Science ®Google Scholar
• HARKER LA, HANSON SR, WILCOX JN, KELLY AB: Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis (1996) 26:76.
   PubMedGoogle Scholar
• ORVIM U, BARSTAD RM, ORNING L, et al.: Antithrombotic efficacy of inactivated active site recombinant Factor VIIa is shear dependent in human blood. Arterioscler. Thromb. Vasc. Biol. (1997) 17:3049.
   PubMed Web of Science ®Google Scholar
• KJALKE M, OLIVER JA, MONROE DM, et al.: The effect of active site-inhibited Factor VIIa on tissue factor- initiated coagulation using platelets before and after aspirin administration. Thromb. Haemost. (1997) 78:1202.
   PubMed Web of Science ®Google Scholar
• RAGNI M, GOLINO P, CIRILLO P, et al.: Inactivated Factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis. Cardiologia (1996) 41:51.
   PubMedGoogle Scholar
• RONNING HF, RISOEN UC, ORNING L, SLETTEN K, SAKARIASSEN KS: Synthetic peptide analogs of tissue factor and Factor VII which inhibit Factor Xa formation by the tissue factor/Factor VIIa complex. Thromb. Res. (1996) 84:73.
   PubMed Web of Science ®Google Scholar
• RAGOSTA M, GIMPLE LW, GERTZ SD, et al.: Specific Factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation (1994) 89:1262.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, MALYCKY JL, RAO JS, et al.: Selective inhibition of Factor Xa is more efficient than Factor VIIa- tissue factor complex blockade at facilitating coronary thrombolysis in the canine model. J. Am. Coll. Cardiol. (1996) 28:1858.
   PubMed Web of Science ®Google Scholar
• BENEDICT CR, RYAN J, TODD J, et al.: Active site-blocked Factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood (1993) 81:2059.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA, MEAGHER EA: Antiplatelet drugs. Eur. J. Clin. Invest. (1994) 24 (Suppl. 1):46.
   PubMedGoogle Scholar
• VERSTRAETE M: Modulating platelet function with selective thrombin inhibitors. Haemostasis (1996) 26 (Suppl 4):70.
   PubMedGoogle Scholar
• MONCADA S, VANE JR: Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. New Engl. J. Med. (1979) 300:1142.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA: Dipyridamole. New Engl. J. Med. (1987) 316:1247.
   PubMed Web of Science ®Google Scholar
• GRESELE P, ARNOUT J, DECKMYN H, VERMYLEN J: Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb. Haemost. (1986) 55:12.
   PubMed Web of Science ®Google Scholar
• OATES JA, FITZGERALD GA, BRANCH RA, JACKSON EK, KNAPP HR, ROBERTS LJD: Clinical implications of prostaglandin and thromboxane A2 formation (1). New Engl. J. Med. (1988) 319:689.
   PubMed Web of Science ®Google Scholar
• OATES JA, FITZGERALD GA, BRANCH RA, JACKSON EK, KNAPP HR, ROBERTS LJD: Clinical implications of prostaglandin and thromboxane A2 formation (2). New Engl. J. Med. (1988) 319:761.
   PubMed Web of Science ®Google Scholar
• NICOLINI FA, MEHTA JL, NICHOLS WW, SALDEEN TG, GRANT M: Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation (1990) 81:1115.
   PubMed Web of Science ®Google Scholar
• TOPOL EJ, ELLIS SG, CALIFF RM, et al.: Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. J. Am. Coll. Cardiol. (1989) 14:877.
   PubMed Web of Science ®Google Scholar
• DARIUS H, NIXDORFF U, ZANDER J, RUPPRECHT HJ, ERBEL R, MEYER J: Effects of ciprostene on restenosis rate during therapeutic transluminal coronary angioplasty. Agents Actions Suppl. (1992) 37:305.
   PubMedGoogle Scholar
• FIDDLER GI, LUMLEY P: Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation (1990) 81:169.
   Google Scholar
• VERSTRAETE M: The PACK trial: morbidity and mortality effects of ketanserin. Prevention of Atherosclerotic Complications. Vasc. Med. (1996) 1:135.
   PubMedGoogle Scholar
• Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group. Br. Med. J. (1989) 298:424.
   PubMed Web of Science ®Google Scholar
• DEFREYN G, BERNAT A, DELEBASSEE D, MAFFRAND JP: Pharmacology of ticlopidine: a review. Semin. Thromb. Hemost. (1989) 15:159.
   PubMed Web of Science ®Google Scholar
• BALSANO F, RIZZON P, VIOLI F, et al.: Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation (1990) 82:17.
   PubMed Web of Science ®Google Scholar
• BOSSAVY JP, THALAMAS C, SAGNARD L, et al.: A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood (1998) 92:1518.
   PubMed Web of Science ®Google Scholar
• HERBERT JM, BERNAT A, SAMAMA M, MAFFRAND JP: The anti-aggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat. Thromb. Haemost. (1996) 76:94.
   PubMed Web of Science ®Google Scholar
• ROALD HE, BARSTAD RM, KIERULF P, et al.: Clopidogrel-a platelet inhibitor which inhibits thrombogenesis in non- anticoagulated human blood independently of the blood flow conditions. Thromb. Haemost. (1994) 71:655.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, COLLER BS, CHANG AC, et al.: 7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coll. Blood (1997) 89: 4078.
   PubMed Web of Science ®Google Scholar
• AMMAR T, SCUDDER LE, COLLER BS: In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation (1997) 95:614.
   PubMed Web of Science ®Google Scholar
• COLLER BS, ANDERSON KM, WEISMAN HF: The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Haemostasis (1996) 26 (Suppl. 4) :285.
   PubMedGoogle Scholar
• GOLD HK, COLLER BS, YASUDA T, et al.: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation (1988) 77:670.
   PubMed Web of Science ®Google Scholar
• COLLER BS: A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. (1985) 76:101.
   PubMed Web of Science ®Google Scholar
• BEGUIN S, LINDHOUT T, HEMKER HC: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb. Haemost. (1989) 61:25.
   PubMed Web of Science ®Google Scholar
• KEULARTS IM, BEGUIN S, DE ZWAAN C, HEMKER HC: Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb. Haemost. (1998) 80:370.
   PubMed Web of Science ®Google Scholar
• REVERTER JC, BEGUIN S, KESSELS H, KUMAR R, HEMKER HC, COLLER BS: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J. Clin. Invest. (1996) 98:863.
   PubMed Web of Science ®Google Scholar
• •First demonstration that an anti-aggregant does influence thrombin generation.
   Google Scholar
• BEGUIN S, KUMAR R: Thrombin, fibrin and platelets: a resonance loop in which von Willebrand factor is a necessary link. Thromb. Haemost. (1997) 78:590.
   PubMed Web of Science ®Google Scholar
• BEGUIN S, KUMAR R, KEULARTS I, SELIGSOHN U, COLLER BS, HEMKER HC: Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. (1999) Blood 93:564–70.
   PubMed Web of Science ®Google Scholar
• •Demonstration that fibrin is thrombogenic and acts through von Willebrand factor.
   Google Scholar
• CHIU HM, HIRSH J, YUNG WL, REGOECZI E, GENT M: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood (1977) 49:171.
   PubMed Web of Science ®Google Scholar
• BASU D, GALLUS A, HIRSH J, CADE J: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New Engl. J. Med. (1972) 287:324.
   PubMed Web of Science ®Google Scholar
• HULL RD, RASKOB GE, HIRSH J, et al.: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New Engl. J. Med. (1986) 315:1109.
   PubMed Web of Science ®Google Scholar
• ANAND S, GINSBERG JS, KEARON C, GENT M, HIRSH J: The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch. Intern. Med. (1996) 156:1677.
   PubMed Web of Science ®Google Scholar
• ELG M, GUSTAFSSON D, DEINUM J: The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb. Haemost. (1997) 78:1286.
   PubMed Web of Science ®Google Scholar
• POLLER L, VAN DEN BESSELAAR AM, JESPERSEN J, TRIPODI A, HOUGHTON D: The European Concerted Action on Anticoagulation (ECAA): field studies of coagulometer effects on the 1ST of ECAA thromboplastins. Thromb. Haemost. (1998) 80:615.
   PubMed Web of Science ®Google Scholar
• NOWAK G, BUCHA E: Quantitative determination of hirudin in blood and body fluids. Semin. Thromb. Hemost. (1996) 22:197.
   PubMed Web of Science ®Google Scholar
• BERRY CN, LUNVEN C, GIRARDOT C, et al.: Ecarin clotting time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat. Thromb. Haemost. (1998) 79:228.
   PubMed Web of Science ®Google Scholar
• SAKARIASSEN KS, AARTS PA, DE GROOT PG, HOUDIJK WP, SIXMA JJ: A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J. Lab. Clin. Med. (1983) 102:522.
   PubMed Web of Science ®Google Scholar
• SAKARIASSEN KS, KUHN H, MUGGLI R, BAUMGARTNER HR: Growth and stability of thrombi in flowing citrated blood: assessment of platelet-surface interactions with computer-assisted morphometry. Thromb. Haemost. (1988) 60:392.
   PubMed Web of Science ®Google Scholar
• HANSON SR, SAKARIASSEN KS: Blood flow and antithrombotic drug effects. Am. Heara (1998) 135:S132.
   PubMed Web of Science ®Google Scholar
• BADIMON L, BADIMON JJ, GALVEZ A, CHESEBRO JH, FUSTER V: Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis (1986) 6:312.
   PubMedGoogle Scholar
• BOSSAVY JP, SAKARIASSEN KS, BARRET A, BONEU B, CADROY Y: A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb. Haemost. (1998) 79:162.
   PubMed Web of Science ®Google Scholar
• BARSTAD RM, ROALD HE, CUI Y, TURITTO VT, SAKARIASSEN KS: A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well- defined stenoses. Arterioscler. Thromb. (1994) 14:1984.
   PubMedGoogle Scholar
• HOLME PA, ORVIM U, HAMERS MJ, et al.: Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17:646.
   PubMed Web of Science ®Google Scholar
• DIQUELOU A, LEMOZY S, DUPOUY D, BONEU B, SAKARIASSEN K, CADROY Y: Effect of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface. Blood (1994) 84:2206.
   PubMed Web of Science ®Google Scholar
• HEMKER HC, WILLEMS GM, BEGUIN S: A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb. Haemost. (1986) 56:9.
   PubMed Web of Science ®Google Scholar
• HEMKER HC, BEGUIN S: Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb. Haemost. (1995) 74:134.
   PubMed Web of Science ®Google Scholar
• HERAULT JP, PEYROU V, SAVI P, BERNAT A, HERBERT JM: Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet- mediated thrombin generation in vitro and in vivo. Thromb. Haemost. (1998) 79:383.
   PubMed Web of Science ®Google Scholar
• PEYROU V, BEGUIN S, BONEU B, HEMKER HC: The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma-the need for using absolute anti-Factor Xa and antithrombin activities. Thromb. Haemost. (1997) 77:312.
   PubMed Web of Science ®Google Scholar
• WIELDERS S, MUKHERJEE M, MICHIELS J, et al.: The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb. Haemost. (1997) 77:629.
   PubMed Web of Science ®Google Scholar
• A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet (1980) 2:989.
   PubMed Web of Science ®Google Scholar
• NERI SERNERI GG, ROVELLI F, GENSINI GF, PIRELLI S, CARNOVALI M, FORTINI A: Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet (1987) 1:937.
   PubMed Web of Science ®Google Scholar
• •References 46 and 47 together demonstrate that thrombin inhibition inhibits arterial thrombi, independent of the mechanism of thrombin inhibition.
   Google Scholar
• KUMAR R, BEGUIN S, HEMKER HC: The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb. Haemost. (1994) 72:713.
   PubMed Web of Science ®Google Scholar
• KUMAR R, BEGUIN S, HEMKER HC: The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb. Haemost. (1995) 74:962.
   PubMed Web of Science ®Google Scholar
• HEMKER HC, HESS B: Analysis and Simulation of Biochemical Systems. Elsevier, Amsterdam, Holland (1972).
   Google Scholar
• YIN ET, WESSLER S, STOLL PJ: Biological properties of the naturally occurring plasma inhibitor to activated Factor X. J. Biol. Chem. (1971) 246:3703.
   PubMed Web of Science ®Google Scholar
• WESSLER S, YIN ET: Theory and practice of minidose heparin in surgical patients. A status report. Circulation (1973) 47:671.
   PubMed Web of Science ®Google Scholar
• ROSING J, TANS G, GOVERS-RIEMSLAG JW, ZWAAL RF, HEMKER HC: The role of phospholipids and Factor Va in the prothrombinase complex. J. Biol. Chem. (1980) 255:274.
   PubMed Web of Science ®Google Scholar
• PIETERS J, LINDHOUT T, HEMKER HC: In situ-generated thrombin is the only enzyme that effectively activates Factor VIII and Factor V in thromboplastin-activated plasma. Blood (1989) 74:1021.
   PubMed Web of Science ®Google Scholar
• BARUCH D, HEMKER HC, LINDHOUT T: Kinetics of thrombin-induced release and activation of platelet Factor V. Eur. J. Biochem. (1986) 154:213.
   PubMedGoogle Scholar
• BILLY D, SPEIJER H, LINDHOUT T, HEMKER HC, WILLEMS GM: Inhibition of prothrombinase at macroscopic lipid membranes: competition between antithrombin and prothrombin. Biochemistry (1995) 34:13699.
   PubMed Web of Science ®Google Scholar
• BILLY D, SPEIJER H, WILLEMS G, HEMKER HC, LINDHOUT T: Prothrombin activation by prothrombinase in a tubular flow reactor. J. Biol. Chem. (1995) 270:1029.
   PubMed Web of Science ®Google Scholar
• BILLY D, BRIEDE J, HEEMSKERK JW, HEMKER HC, LINDHOUT T: Prothrombin conversion under flow conditions by prothrombinase assembled on adherent platelets. Blood Coagul. Fibrinolysis (1997) 8:168.
   PubMed Web of Science ®Google Scholar
• LORMEAU JC, HERAULT JP: The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of Factor Xa. Thromb. Haemost. (1995) 74:1474.
   PubMed Web of Science ®Google Scholar
• BEGUIN S, LINDHOUT T, HEMKER HC: The mode of action of heparin in plasma. Thromb. Haemost. (1988) 60:457.
   PubMed Web of Science ®Google Scholar
• •Demonstration that anti-Factor Xa activity of heparin contributes little to heparin action.
   Google Scholar
• BEGUIN S, MARDIGUIAN J, LINDHOUT T, HEMKER HC: The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Thromb. Haemost. (1989) 61:30.
   PubMed Web of Science ®Google Scholar
• BEGUIN S, WIELDERS S, LORMEAU JC, HEMKER HC: The mode of action of CY216 and CY222 in plasma. Thromb. Haemost. (1992) 67:33.
   PubMed Web of Science ®Google Scholar
• PETITOU M, DUCHAUSSOY P, JAURAND G, et al.: Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J. Med. Chem. (1997) 40:1600.
   PubMed Web of Science ®Google Scholar
• PETITOU M, DUCHAUSSOY P, LEDERMAN I, et al.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide 0-(2-deoxy-2-sulfamido-6-0-sulfo-alpha-D-glucopyranosyl)- (1-4 )-0-(beta-D-glucopyranosyluronic acid)-(1-4)-0-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glu copyranosyl)-(1-4)-0-(2-0-sulfo-alpha-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-0-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr. Res. (1986) 147:221.
   PubMed Web of Science ®Google Scholar
• •The first synthesis of an active polysaccharide with heparin-action.
   Google Scholar
• DOL F, PETITOU M, LORMEAU JC, et al.: Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate. J. Lab. Clin. Med. (1990) 115:43.
   PubMedGoogle Scholar
• AGUEJOUF O, OUALANE FA, INAMO J, et al.: The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis. Semin. Thromb. Hemost. (1996) 22:327.
   PubMedGoogle Scholar
• BELLAMY F, HORTON D, MILLET J, PICART F, SAMRETH S, CHAZAN JB: Glycosylated derivatives of benzophenone, benzhydrol, and benzhydril as potential venous antithrombotic agents. J. Med. Chem. (1993) 36:898.
   PubMed Web of Science ®Google Scholar
• BODE W, MAYR I, BAUMANN U, HUBER R, STONE SR, HOFSTEENGE J: The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. Embo. J. (1989) 8:3467.
   PubMed Web of Science ®Google Scholar
• •Classical paper on which much of the stereochemistry of thrombin inhibitors is based.
   Google Scholar
• SANDERSON PE, NAYLOR-OLSEN AM: Thrombin inhibitor design. Curr. Med. Chem. (1998) 5:289.
   PubMed Web of Science ®Google Scholar
• GIESSEN PLA et al.: Blood borne tissue factor: a new view on thrombosis. Proc. Natl. Acad. Sci. USA (In Press).
   PubMedGoogle Scholar